Faculty

Back to Index
Howard Liebman, MD
Professor of Medicine, Don Feinstein Chair in Hematology
Medicine
NOR 3466 Health Sciences Campus Los Angeles
+1 323 865 3950

Overview

Since 1999, Dr. Liebman is the author or co-author of over 100 medical articles and chapters and has led well over a hundred lectures across the United States, South America, Europe and Japan on a variety of medical topics. He has also been the recipient of millions of dollars in research grants, reviewed a number of medical journals and is a former Chair of the Massachusetts Governor’s Task Force subcommittee on experimental therapies and clinical trials for AIDS. In addition to his academic responsibilities, Dr. Liebman is an attending staff member of the LAC+USC Medical Center, the USC/Norris Comprehensive Cancer Center and the Keck Hospital of USC.

Dr. Liebman also is on the forefront of research in thrombotic and hemorrhagic disorders. His lab is currently studying the genetic risk factors responsible for thrombotic diseases including venous thrombosis, pulmonary embolism, arterial thrombosis and thrombosis associated with cancer chemotherapy. Additional studies are elucidating the role of prothrombotic defects in developing osteonecrosis. He has also been the principle investigator on a number of clinical trials in the management of immune thrombocytopenia. His research group has made important discoveries on the role of infectious agents in the development of immune thrombocytopenia. Dr. Liebman is also internationally known for his work in the relationships between venous thrombotic disease and underlying malignancy and has served on the Cancer and Thrombosis Guideline Committee of the American Society of Clinical Oncology.

Publications

Autoimmune Hemolytic Anemia. Med Clin North Am. 2017 Mar; 101(2):351-359. View in: PubMed

Comparison of two dosing schedules for subcutaneous injections of low-dose anti-CD20 veltuzumab in relapsed immune thrombocytopenia. Haematologica. 2016 Nov; 101(11):1327-1332. View in: PubMed

Immune modulation for autoimmune disorders: evolution of therapeutics. Semin Hematol. 2016 Apr; 53 Suppl 1:S23-6. View in: PubMed

Incidental venous thromboembolic events in cancer patients: what we know in 2016. Thromb Res. 2016 Apr; 140 Suppl 1:S18-20. View in: PubMed

Life-threatening delayed hyperhemolytic transfusion reaction in a patient with sickle cell disease: effective treatment with eculizumab followed by rituximab. Transfusion. 2015 Oct; 55(10):2398-403. View in: PubMed

Management of immune-mediated cytopenias in pregnancy. Autoimmun Rev. 2015 Sep; 14(9):806-11. View in: PubMed

Venous thromboembolism prophylaxis and treatment in patients with cancer: american society of clinical oncology clinical practice guideline update 2014. J Clin Oncol. 2015 Feb 20; 33(6):654-6. View in: PubMed

Approach to the management of incidental venous thromboembolic events in patients with cancer. J Natl Compr Canc Netw. 2014 Nov; 12(11):1557-60. View in: PubMed

Thrombocytopenia in cancer patients. Thromb Res. 2014 May; 133 Suppl 2:S63-9. View in: PubMed

Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials. Eur J Haematol. 2013 Nov; 91(5):423-36. View in: PubMed

Low-dose anti-CD20 veltuzumab given intravenously or subcutaneously is active in relapsed immune thrombocytopenia: a phase I study. Br J Haematol. 2013 Sep; 162(5):693-701. View in: PubMed

Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013 Jun 10; 31(17):2189-204. View in: PubMed

Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. Blood. 2013 Apr 4; 121(14):2596-606. View in: PubMed

Predictive model of venous thromboembolism in endometrial cancer. Gynecol Oncol. 2013 Mar; 128(3):544-51. View in: PubMed

Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). Br J Haematol. 2013 Feb; 160(4):530-7. View in: PubMed

Eculizumab therapy results in rapid and sustained decreases in markers of thrombin generation and inflammation in patients with PNH independent of its effects on hemolysis and microparticle formation. Thromb Res. 2012 Sep; 130(3):361-8. View in: PubMed

Treating venous thromboembolism in patients with cancer. Expert Rev Hematol. 2012 Apr; 5(2):201-9. View in: PubMed

Symptoms adversely impact survival among patients with cancer and unsuspected pulmonary embolism. J Clin Oncol. 2011 Nov 1; 29(31):4208-9; author reply 4209-10. View in: PubMed

Diagnosis and management of immune thrombocytopenia in the era of thrombopoietin mimetics. Hematology Am Soc Hematol Educ Program. 2011; 2011:384-90. View in: PubMed

Clinical roundtable monograph. The oncologist's role in management of venous thromboembolism. Clin Adv Hematol Oncol. 2011 Jan; 9(1):suppl 1-15. View in: PubMed

What do healthcare providers ask their patients with immune thrombocytopenia? Am J Hematol. What do healthcare providers ask their patients with immune thrombocytopenia? Am J Hematol. 2010 Aug; 85(8):629-31. View in: PubMed

Increased microparticle tissue factor activity in cancer patients with Venous Thromboembolism. Thromb Res. 2010 Jun; 125(6):511-2. View in: PubMed

The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation. Hematol Oncol Clin North Am. 2009 Dec; 23(6):1155-61. View in: PubMed

Preface. Hematol Oncol Clin North Am. 2009 Dec; 23(6):xi. View in: PubMed

Thyroid disease in patients with immune thrombocytopenia. Hematol Oncol Clin North Am. 2009 Dec; 23(6):1251-60. View in: PubMed

Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res. 2009 Nov 15; 15(22):6830-40. View in: PubMed

The ITP syndrome: pathogenic and clinical diversity. Blood. 2009 Jun 25; 113(26):6511-21. View in: PubMed

Pathobiology of secondary immune thrombocytopenia. Semin Hematol. 2009 Jan; 46(1 Suppl 2):S2-14. View in: PubMed

Recognizing and treating secondary immune thrombocytopenic purpura associated with lymphoproliferative disorders. Semin Hematol. 2009 Jan; 46(1 Suppl 2):S33-6. View in: PubMed

Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia. Biologics. 2009; 3:57-62. View in: PubMed

Managing cancer-related venous thromboembolic disease: low-molecular-weight heparins and beyond. Expert Rev Hematol. 2008 Dec; 1(2):175-82. View in: PubMed

Subclinical haemostatic activation and current surgeon volume predict bleeding with open radical retropubic prostatectomy. BJU Int. 2008 Nov; 102(9):1086-91. View in: PubMed

Heparin-platelet factor 4 antibodies are frequent after vascular surgery but are not a frequent cause of graft thrombosis or thrombocytopenia. J Vasc Surg. 2008 Aug; 48(2):377-81. View in: PubMed

Heparin-induced thrombocytopenia: diagnosis and management. Vascular. 2008 Mar-Apr; 16 Suppl 1:S71-6. View in: PubMed

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008 Feb 2; 371(9610):395-403. View in: PubMed

Viral-associated immune thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2008; 212-8. View in: PubMed

Immune thrombocytopenia (ITP): an historical perspective. Hematology Am Soc Hematol Educ Program. 2008; 205. View in: PubMed

American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol. 2007 Dec 1; 25(34):5490-505. View in: PubMed

The role of oral anticoagulants in tumor biology. Semin Thromb Hemost. 2007 Oct; 33(7):695-8. View in: PubMed

Other immune thrombocytopenias. Semin Hematol. 2007 Oct; 44(4 Suppl 5):S24-34. View in: PubMed

Secondary immune thrombocytopenic purpura. Curr Opin Hematol. 2007 Sep; 14(5):557-73. View in: PubMed

A closer look at intravascular hemolysis (IVH) following intravenous anti-D for immune thrombocytopenic purpura (ITP). Blood. 2007 Jun 15; 109(12):5527; author reply 5528. View in: PubMed

Unsuspected pulmonary emboli in cancer patients: clinical correlates and relevance. J Clin Oncol. 2006 Oct 20; 24(30):4928-32. View in: PubMed

Progressive prothrombotic state in women with advancing HIV disease. J Acquir Immune Defic Syndr. 2006 Aug 15; 42(5):572-7. View in: PubMed

Rituximab treatment for resistant antiphospholipid syndrome. J Rheumatol. 2006 Feb; 33(2):355-7. View in: PubMed

Current perspectives on primary prophylaxis and patient risk factors for venous thromboembolism in the cancer patient. Cancer Control. 2005 Sep; 12 Suppl 1:11-6. View in: PubMed

Hepatitis C virus-related thrombocytopenia: clinical and laboratory characteristics compared with chronic immune thrombocytopenic purpura. Br J Haematol. 2005 Jun; 129(6):818-24. View in: PubMed

Meeting report. Acute promyelocytic leukemia-associated coagulopathy, 21 January 2004, London, United Kingdom. Leuk Res. 2005 Mar; 29(3):347-51. View in: PubMed

Subcutaneous lepirudin for heparin-induced thrombocytopenia and when other anticoagulants fail: illustrative cases. Clin Adv Hematol Oncol. 2004 Jun; 2(6):382-4; discussion 384-6. View in: PubMed

Successful treatment of refractory pure red cell aplasia associated with lymphoproliferative disorders with the anti-CD52 monoclonal antibody alemtuzumab (Campath-1H). Br J Haematol. 2003 Oct; 123(2):278-81. View in: PubMed

Thromboembolic complications of cancer: epidemiology, pathogenesis, diagnosis, and treatment. Am J Hematol. 2003 Jan; 72(1):43-52. View in: PubMed

Thrombosis in patients with paroxysmal noctural hemoglobinuria is associated with markedly elevated plasma levels of leukocyte-derived tissue factor. Thromb Res. 2003; 111(4-5):235-8. View in: PubMed

Anticoagulation is an effective treatment for aortic mural thrombi. J Vasc Surg. 2002 Oct; 36(4):713-9. View in: PubMed

Detection of lupus anticoagulant identifies patients with autoimmune haemolytic anaemia at increased risk for venous thromboembolism. Br J Haematol. 2002 Sep; 118(4):1166-9. View in: PubMed

Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation. Thromb Haemost. 2002 Aug; 88(2):213-20. View in: PubMed

Powered bySC CTSI